June 2012 January 2014 October 2009 May 2012 Staff Rheumatologist, Diagnostic Clinic, Clearwater, FL Staff Rheumatologist, Arthritis Associates, Palm Harbor, FL 2008 2012 Co-Investigator, Arthritis Research of Florida, Palm Harbor, FL October 1991 October 2009 Rheumatologist, Private Practice, Palm Harbor & Safety Harbor, FL 2003 2005 Investigator, Gulf Coast Pharmaceutical Research, Inc., New Port Richey, FL 1996 2008 Co-Investigator, Tampa Bay Medical Research, Inc., Clearwater, FL October 1991 March 2004 December 1987 October 1991 February 1986 December 1987 August 1985 February 1986 January 1983 June 1983 Rheumatologist, Medical Associates of Florida, (Clinic without Walls) Rheumatologist, Mease Clinic, New Port Richey & Safety Harbor, FL Rheumatologist, Private Practice, Bayonet Point & Safety Harbor, FL Employed Position, New Port Richey, FL Internist, ODA Primary Care Satellite Clinic and Kings Brook Hospital Medical Clinic, Brooklyn, NY PROFESSIONAL MEMBERSHIPS American College of Rheumatology American College of Physicians Texas Medical Society RESEARCH ACTIVITIES LECTURES Isolation of IgG RF and Development of an ELISA Assay. Under directorship of Dr. Ed Pisko, Bowman Gray School of Medicine. 1983-1985 Immunological Research Assistant at Sloan Kettering Institute. 1974 CME lectures given to Medical Staff of Mease, Bayonet Point and Morton Plant Hospitals Community talks through Mease and Morton Plant Hospitals Community talks through local Arthritis Foundation and Abbott Laboratories
ABSTRACTS Goodman, et. Al. A Micromodification of the Sheep Cell Agglutination Test for Rheumatoid Factor: Clinical Usefulness of Combined Testing with the Latex Agglutination Test for the Diagnosis of RA. Clin Res 32:864A, 1984. Above abstract presented at the American Federation for Clinical Research. January 31, 1985, New Orleans, LA. BIBLIOGRAPHY Goodman, et. Al. Analysis of Combined Rheumatoid Factor Determinations by the RA Latex and Sheep Cell Agglutination Tests and the ARA Criteria for RA. Journal of Rheumatology. CLINICAL RESEARCH EXPERIENCE 1. Co-Investigator of a One-Year, Open Label Study of the Efficacy, Safety and Tolerance of Pirazolac b.i.d. in Patients with RA. Turner, Goodman, et. al. 1983-1985 2. Co-Investigator of the Comparison of Auranofin and Placebo in the Treatment of Psoriatic Arthritis. Wise, Turner,Goodman, et. al. 1983-1985 3. Co-Investigator of the Comparison of the Tolerability and Effiacy of the 500 mg b.i.d. Dose of Naproxen, the 1000 mg Controlled Release Formulation of Naproxen Administered Once Daily and 20 mg q.d. of Piroxicam Administered Once Daily in Patients with Active RA. Turner, Goodman, et. al. 1983-1985 4. Co-Investigator- Amflutizole vs. Allopurinol for Gout Due to Hyperuricemia. Agudelo, Goodman, et. al. 1983-1985 5. Principal Investigator of a Phase 3, Multicenter Study of the safety of Human Anti- TNF Monocolonal Antibody D2E7 in Subjects with active Rheumatoid Arthritis. Protocol Number M02-498. Sponsor: Abbott. 2002-2010 6. Principal Investigator of a Phase 4 trial of Humira Efficacy Response Optimization in Subjects with Active Rheumatoid Arthritis. Protocol Number M04-684 (HERO). Sponsor: Abbott. 2004 7. Co-Investigator of a Phase 4, Randomized, Double-Blind, Parallel Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing XXX With XXX and XXX. Protocol number A319117 (PRECISION). Sponsor: Pfizer. 2006-2008 8. Co-Investigator of a Phase 3, Randomized, Double Blind, Parallel Group Study of the Mechanism of Action to Evaluate the Effects of il-6 Receptor Blockade with XXX on Lipids, Arterial Stiffness and Markers of Atherogenic Risk in Patients with Moderate to Severe Active Rheumatoid Arthritis. Protocol number WA19923. Sponsor: Hoffmann-La Roche. 2007-2008
9. Co-Investigator of a Phase 3, Randomized, Double-Blind, Controlled Study of the Long Term Analgesic Efficacy and Safety of XXX Alone or in Combination with Non-steroidal Antiinflammatory Drugs (NSAIDS) vs NSAIDS Alone in Patients with Osteoarthritis of the Knee and Hip. Protocol number: A4091025. Sponsor: Pfizer. 2008-2010 10. Co-Investigator of a Phase 3, Randomized, Double-Blind, Parallel, International Study to Evaluate the Safety and Efficacy of XXX Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to MTX Therapy. Protocol numbers: ACT4394g1, WA20496 (FEATURE). Sponsor: Genentech Inc. 2008-2009 11. Co-Investigator of a Phase 1, Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage Study of the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous XXX in Patients with Rheumatoid Arthritis. Protocol number: CDT4478g. Sponsor: Genentech, Inc. 2008-2009 12. Co-Investigator of a Phase 3, Open-Label, Randomized Study to Evaluate Safety, Tolerability and Efficacy of XXX in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDS and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs. Protocol number: ML22533. Sponsor: Hoffman-La Roche. 2009-2011. 13. Co-Investigator of a Phase 3, 2-year, Randomized, Head to Head, Single Blind Study to Compare the Efficacy and Safety of Subcutaneous XXX vs. XXX, Both with Background MTX, in Biologic Naïve Subjects with Rheumatoid Arthritis. Protocol: (AMPLE) Sponsor: Bristol- Myers Squibb. 2009-2010 14. Co-Investigator of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety of XXX for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy. Protocol number: IL1TGA0815 (RE-SURGE). Sponsor: Regeneron Pharmaceuticals. 2009-2010 15. Principal Investigator of a Phase 3, Randomized, Double-Blind, Parallel Group Study Assessing the Impact of MTX Discontinuation on the Efficacy of Subcutaneous Tocilizumab with MTX Therapy. Protocol number: ML28776 (COMP-ACT) Sponsor: Genentech Inc. 2014-Current 16. Principal Investigator of a Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csdmards) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bdmards). Protocol number: M13-542. Sponsor: AbbVie. January 2016-present 17. Principal Investigator of a Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) in subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX. Protocol number: M15-555. Sponsor: AbbVie. January 2016-present. 18 Principal Investigator of a Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumabin Subjects with Moderately to Severely Active Rheumatoid Arthritis who are on a Stable Background of Methotrexate (MTX) and who Have an Inadequate
Response to MTX (MTX-IR). Protocol number: M14-465: Sponsor: AbbVie. January 2016 present. 19 Principal Investigator of a Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis. Protocol number: M13-545: Sponsor: AbbVie. January 2016 present. 20 Principal Investigator of a Phase 3, Randomized Double -blind, Placebo-and Active-controlled, Multicenter, Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis What Have an Inadequate Response to Methotrexate. Protocol number: GS-US-417-0301: Sponsor: Gilead. April 2016 present. 21 Principal Investigator of a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-Rheumatic Drug(s) (csdmards) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment. Protocol number: GS-US-417-0302: Sponsor: Gilead. April 2016 present. 22 Principal Investigator of a Phase 3, Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy. Protocol number: GS-US417-0303: Sponsor: Gilead. April 2016 present.